Stiver H G, Graves P, Meiklejohn G, Schröter G, Eickhoff T C
Infect Immun. 1977 Jun;16(3):738-41. doi: 10.1128/iai.16.3.738-741.1977.
Before and after vaccination with a commercial inactivated influenza vaccine containing A/Aichi/2/68 (H3N2) and B/Massachusetts/1/71 antigens, the serum hemagglutination inhibition antibody titers to homologous and heterologous strains of A and B influenza viruses were measured in 45 renal transplant patients and 66 healthy controls (62 for the B strains). At least a fourfold titer rise to the homologous A strain occurred in 14 of 45 transplant patients (31%) versus 37 of 66 controls (56%). Fourfold or greater heterologous A rises occurred in only 8 of 45 transplant patients (18%) compared with 40 of 60 controls (61%). In both the homologous and heterologous B responses, at least fourfold hemagglutination inhibition titer rises were seen in significantly fewer transplant patients than control subjects. In the transplant group, no correlation was observed between degree of antibody response and age, previous influenza vaccination, percentage of patients initially seronegative, time since transplantation, dose of immunosuppressive drugs, level of renal function, or nature of original renal disease.
在用含有A/爱知/2/68(H3N2)和B/马萨诸塞/1/71抗原的市售灭活流感疫苗进行接种前后,对45例肾移植患者和66例健康对照者(针对B株为62例)测定了针对甲型和乙型流感病毒同源及异源株的血清血凝抑制抗体效价。45例移植患者中有14例(31%)针对同源甲型毒株的效价至少升高了四倍,而66例对照者中有37例(56%)。45例移植患者中只有8例(18%)针对异源甲型毒株的效价升高了四倍或更多,相比之下60例对照者中有40例(61%)。在同源和异源乙型反应中,移植患者中血凝抑制效价至少升高四倍的人数明显少于对照者。在移植组中,未观察到抗体反应程度与年龄、既往流感疫苗接种情况、初始血清阴性患者的百分比、移植后的时间、免疫抑制药物剂量、肾功能水平或原发病性质之间存在相关性。